Or­p­hazyme CEO de­parts for Leo Phar­ma as both com­pa­nies face ma­jor re­struc­tur­ings

Some­one else, it seems, will get the op­por­tu­ni­ty of try­ing to steer Or­p­hazyme back to its for­mer meme­land glo­ry.

In a bit of Dan­ish biotech mu­si­cal chairs, Or­p­hazyme CEO Christophe Bour­don is leav­ing the rare dis­ease biotech to be­come CEO of the der­ma­tol­ogy-fo­cused Leo Phar­ma, the com­pa­nies an­nounced. Bour­don’s de­par­ture, set for April 1, will come bare­ly a year af­ter he joined, al­though it was not an un­event­ful one.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER